---
schema_version: "secwatch.filing_event.v1"
accession: "0000882095-25-000041"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2025-10-06T23:59:59+00:00"
generated_at: "2026-05-17T04:40:58.986888+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gilead settles Biktarvy patent litigations; no generic entry expected before April 1, 2036

## Summary
- Settlements with Lupin, Cipla, and Laurus Labs resolve patent disputes over generic Biktarvy.
- No generic version of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) permitted in US before April 1, 2036.
- Agreements are subject to standard acceleration provisions.
- Biktarvy is Gilead's leading HIV treatment; extending exclusivity protects significant revenue.

## SEC filing metadata
- accession: 0000882095-25-000041
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2025-10-06T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000088209525000041/0000882095-25-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000088209525000041/gild-20251006.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000882095-25-000041
- JSON: https://secwatch.observer/filing/0000882095-25-000041.json
- Plain text: https://secwatch.observer/filing/0000882095-25-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.